Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 45.86% is 14% below its 5-year average of 53.13%, near the high end of its 5-year range (-2904.95%–100.00%).
54.14% below its 12-month average of 100.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
45.86%
GROSS MARGIN AVG TTM
100.00%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
53.13%
GROSS MARGIN AVG 10Y
26.56%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-54.14%
CURRENT VS 3Y AVG
-54.14%
CURRENT VS 5Y AVG
-13.68%
CURRENT VS 10Y AVG
+72.63%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+10.83%
vs the sector median at left
Market Cap
$356.90M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
66.67%
Market Cap
$357.08M
Gross Margin
98.15%
TTM Avg
96.49%
3Y Avg
98.25%
5Y Avg
98.83%
Market Cap
$356.54M
Gross Margin
57.21%
TTM Avg
58.46%
3Y Avg
59.89%
5Y Avg
60.54%
Market Cap
$359.44M
Gross Margin
93.73%
TTM Avg
92.44%
3Y Avg
93.34%
5Y Avg
78.89%
Market Cap
$351.80M
Gross Margin
99.32%
TTM Avg
95.85%
3Y Avg
93.96%
5Y Avg
99.79%
Market Cap
$350.53M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$364.12M
Gross Margin
99.87%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ocugen, Inc. (OCGN) | $356.88M | 45.86% | 100.00% | 100.00% | 53.13% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $356.90M | 0.00% | 50.00% | 75.00% | 66.67% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.08M | 98.15% | 96.49% | 98.25% | 98.83% |
| Viemed Healthcare, Inc. (VMD)vs › | $356.54M | 57.21% | 58.46% | 59.89% | 60.54% |
| Embecta Corp. (EMBC)vs › | $357.44M | 59.89% | 63.90% | 65.83% | 67.05% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.44M | 93.73% | 92.44% | 93.34% | 78.89% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $351.80M | 99.32% | 95.85% | 93.96% | 99.79% |
| Turn Therapeutics Inc. (TTRX)vs › | $350.53M | 0.00% | 0.00% | 0.00% | 0.00% |
| Opus Genetics, Inc. (IRD)vs › | $364.12M | 99.87% | 100.00% | 100.00% | 83.33% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $346.66M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
45.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 100.00% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | -90.54% |
| 2023-06-30 | -2904.95% |
| 2023-03-31 | -2196.16% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | -3690.70% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 100.00% |
